2024-09-11 - Analysis Report
## Vertex Pharmaceuticals (VRTX) Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals is a leading biotechnology company focused on developing and commercializing therapies for cystic fibrosis and other serious diseases.

**1. Performance Comparison:**

* **Cumulative Return:** VRTX has returned 107.41%, outperforming the S&P 500 (VOO) which has returned 83.37%. 
* **Outperformance:** VRTX has outperformed the S&P 500 by 24.04%. This represents a relative outperformance of 80.21% compared to its historical range.

**2. Recent Price Movement:**

* **Closing Price:** $471.11
* **5-day Moving Average:** $472.39
* **20-day Moving Average:** $478.97
* **60-day Moving Average:** $481.25

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 37.08. The RSI suggests that the stock is currently in oversold territory.
* **PPO (Percentage Price Oscillator):** -0.33. The negative PPO value indicates a bearish momentum in the stock.
* **Delta_Previous_Relative_Divergence:** -2.9. The negative value suggests a short-term downward trend.
* **Expected Return:** 9.57%. This represents the potential annualized return over the next five years based on current investment.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue | 
|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2023-08-02 | 3.55 | 2.49 B$ |
| 2023-05-07 | 3.55 | 2.49 B$ |

The most recent earnings report (2024-08-02) showed a significant miss in earnings per share. The company reported a loss of $13.92 per share, while analysts were expecting a profit of $4.11 per share. This may explain the recent decline in the stock price. However, revenue remained relatively stable and surpassed analyst expectations. It's important to note that Vertex has a history of strong revenue growth and its pipeline of innovative treatments for cystic fibrosis and other rare diseases remains promising.  

**5. Overall Analysis:**

VRTX has outperformed the market significantly in the past, but its recent performance has been lackluster, possibly due to the recent earnings miss. The technical indicators suggest oversold conditions and a short-term bearish momentum. However, the companyâ€™s long-term prospects remain strong, driven by its innovative drug pipeline and its market-leading position in cystic fibrosis treatment. Investors should carefully consider the company's future earnings and the potential impact of new drug approvals and market competition before making any investment decisions. 

**6. Conclusion:**

While VRTX has shown remarkable growth in the past, its recent earnings miss has impacted investor sentiment and led to a decline in the stock price. The technical indicators suggest oversold conditions and a short-term bearish momentum, but the company's long-term prospects remain strong. Investors should monitor the company's future earnings and the potential impact of new drug approvals and market competition before making any investment decisions. 
